Genomadix’s technology has grown and changed to fit industry needs since the company’s inception in 2005. Below is a timeline of our accomplishments and milestones that has led to the creation of the Genomadix CUBE as you know it today.
2020
Submitted the COVID-19 System to Health Canada for assessment to provide authorization to sell in Canada.
European Commercialization Launch: five distributors signed in Europe.
The TAILOR-PCI study is published in JAMA, featuring the use of the Genomadix RX CYP2C19 Test.
2018
Genomadix CUBE receives CE IVD Certification.
2016
Genomadix CUBE is announced.
The Genomadix Legionella Test launched.
2014
Canada and Korea approve the Genomadix RX CYP2C19 Test.
2013
Genomadix RX receives FDA clearance.
2012
Genomadix RX Technology used in POPular Genetics, 2,488 patient trial.
2010
Genomadix RX receives CE Marking for Europe, Africa, Asia.
2010
Genomadix RX CYP2C19 test introduced.
2006
Genomadix DX DNA Analyzer launched.
2005
Genomadix was founded.
